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Abstract: Helicobacter pylori (Hp)-induced inflammatory reaction leads to a persistent disturbance 
of gastric mucosa and chronic gastritis evidenced by deregulation of tissue self-renewal and local 
fibrosis with the crucial role of epithelial-mesenchym al transition (EMT) in this process. As we 
reported before, Hp activated gastric fibroblasts into cells possessing cancer-associated fibroblast 
properties (CAFs), which secreted factors responsible for EMT process initiation in normal gastric 
epithelial RGM1 cells. Here, we showed that the long-term incubation of RGM1 cells in the 
presence of Hp-activated gastric fibroblast (Hp-AGF) secretome induced their shift towards plastic 
LGR5+/Oct4high/Sox-2high/c-Mychigh/Klf4low phenotype (l.t.EMT+RGM1 cells), while Hp-non-infected 
gastric fibroblast (GF) secretome prompted a permanent epithelial-myofibroblast transition (EMyoT) 
of RGM1 cells favoring LGR- /Oct4high/Sox2low/c-Myclow/Klf4high phenotype (l.t.EMT- RGM1 cells). 
TGFp1 rich secretome from Hp-reprogrammed fibroblasts prompted phenotypic plasticity and EMT 
of gastric epithelium, inducing pro-neoplastic expansion of post-EM T cells in the presence of low 
TGFpR1 and TGFpR2 activity. In turn, TG FpRl activity along with GF-induced TGFpR2 activation 
in l.t.EMT- RGM1 cells prompted their stromal phenotype. Collectively, our data show that infected 
and non-infected gastric fibroblast secretome induces alternative differentiation programs in gastric 
epithelium at least partially dependent on TGFp signaling. Hp infection-activated fibroblasts can 
switch gastric epithelium microevolution towards cancer stem cell-related differentiation program 
that can potentially initiate gastric neoplasm.
Keywords: Helicobacter pylori; gastric cancer; activated fibroblasts; cancer associated 
fibroblasts (CAFs); epithelial-mesenchym al transition (EMT); TGFp1; cancer stem cells; 
epithelial-myofibroblast transition
1. Introduction
Gastric cancer (GC) remains the fourth most common cause of cancer-related deaths worldwide. 
It is estimated that 90% of all stomach tumors are malignant, with gastric adenocarcinoma comprising 
95% of the total number of malignancies [1]. Despite the improvement in surgery, chemo-radiotherapy,
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and targeted therapy, patients still suffer from cancer recurrence and metastasis [2]. These result 
from the biological properties of tumor cells, including their high invasiveness, rapid proliferation, 
and the activity of anti-apoptotic systems [3] leading to considerable GC mortality. The asymptomatic 
gastric infection with the Gram-negative bacterium Helicobacter pylori (H p) accounts for the high 
incidence of cancer recurrence, metastasis, and increased chemoresistance. This WHO-designated class 
I carcinogen considerably interferes with the curative resection of aggressive GCs [1,4], resulting in 
the cascade of events related to the interplay between Hp infection, host factors, and environmental 
factors. The Hp-induced inflammatory reaction leads to a persistent disturbance of gastric mucosa 
and chronic gastritis. This is evidenced by deregulation of tissue self-renewal and local fibrosis 
with the crucial role of epithelial-mesenchym al transition (EMT) in this process [5 ]. Hp induces a 
plethora of different signal transduction processes that trigger a complex multi-step process leading 
to inflammation and carcinogenesis [6- 8]. These pathways are responsible for control of cellular 
responses such as proliferation, apoptosis, epithelial dedifferentiation, and motility. So, it seems 
undiscussable that the interplay between different cell types ranging from gastric epithelial cells, 
glands, immune cells, and stem cells is crucially important for the development and progression of
H. pylori-associated carcinogenesis [9- 11]. Besides cells of the innate and adaptive immune system, 
the tumor microenvironment is to a large degree made up of cancer-associated fibroblasts (CAFs). 
Fibroblasts might be an important Hp target since Necchi [12] identified the presence of Hp not only in 
epithelial cells and intraepithelial intercellular spaces, but also in the underlying lamina propria and 
stromal tumor. Recently, the direct interaction between this bacterial pathogen and fibroblasts has 
been proposed [13], suggesting that Hp interacts with several other cells beyond its direct effect on 
gastric epithelium  s, namely with connective tissue components including fibroblasts.
Transforming growth factor-beta1 (TGFp1) represents a pleiotropic superfamily of cytokines 
belonging to the class of the most potent EMT inducers. TGFp 1 acts via the activation of a 
hetero-oligomeric receptor complex consisting of the type II receptor (TGFp RII) and the type I 
ALK5 receptor (TGFpR1). These complexes activate a range of intracellular signal transduction 
pathways [14] involved in the regulation of a multitude of biological processes including tissue 
homeostasis, angiogenesis, cell migration, and differentiation [15,16]. Under physiological conditions, 
TGFp has been proposed to inhibit cell proliferation [17]. It also induces EMT-type Il-related local 
fibrosis, which otherwise accompanies the inflammatory responses and tissue repair under normal 
conditions. Nevertheless, TGFp1 is also overproduced in many tumors and plays a dual role in 
GC progression and metastasis [17,18]. These events are associated with the limited benefit of GC 
treatment regimens via the stimulatory effect on the tumor stroma, in particular on cancer-associated 
fibroblast formation [18]. CAFs represent an important element of the tumor microenvironment [19- 21] 
responsible for EMT-type III initiation in epithelial cell compartments, which is a prerequisite for 
CAF-induced tumor promotion/progression [22- 25]. Apart from TGFp1, this process is achieved by 
cancer-related secretion of a range of other pro-inflammatory and tumor promoting factors [26- 28].
CAFs can also promote the expansion of cancer stem cells (CSCs) or induce generation of CSCs from 
differentiated cancer cells [29]. Accumulating evidence reveals an intimate link between embryonic 
development, stem cells, and cancer formation [30]. Cancer stem cells share features with true stem 
cells by having the capacity to self-renew in de-differentiated state, to generate heterogeneous types 
of differentiated progeny, and to give rise to the bulk tumor [31,32]. These activities are related 
to the pluripotency circuitry, particularly to so-called "Yamanaka factors" such as Oct4, Klf4, Sox2, 
and c-Myc [30].
TGF p 1-induced EMT has been linked with the acquisition of stem-like characteristics by neoplastic 
cells [33]. At the advanced stages of cancer development, TGFp1 can accelerate cell proliferation, 
induce EMT, and enhance the invasion and migration of stem-like cancer cells, resulting in tumor 
metastasis [17,34]. We recently reported that Hp (cagA+vacA+) induces the activation of gastric 
fibroblasts (Hp-AGFs) into the cells possessing CAF phenotype [35]. Here, we concentrated on the 
long-term effect of Hp-activated gastric fibroblasts (Hp-AGF) secretome on the pattern of phenotypic
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reprogramming of gastric epithelial cells. In particular, we addressed the role of Hp signaling in the 
determination of Hp-AGF-mediated pluripotency of EMT-committed gastric epithelial cells, with a 
special emphasis to the role of TGFp signaling in this process.
2. Materials and Methods
2.1. Bacterial Hp Strain
The Hp strain expressing CagA and VacA cytotoxins (43504 Hp cagA+vacA+ (s1/m1)) was purchased 
from American Type Culture Collection [36,37]. Stock cultures were maintained at -7 0  °C in Brucella 
Broth (Becton Dickinson, New Jersey, NJ, USA), supplemented with 10% fetal bovine serum and 10% 
glycerol. The cultures of bacteria were grown on Columbia Agar with 5% fresh horse blood (BioMerieux, 
Marcy l'Etoile, France). The plates were incubated under microaerophilic conditions at 37 °C for 
3-5  days. Before the co-incubation with fibroblasts, Hp strain was suspended in PBS (Sigma-Aldrich, 
Saint Louis, MO, USA) and immediately transferred to the dishes containing fibroblasts.
2.2. Technique o f Rat Gastric Fibroblasts Isolation and Their Activation towards Fibroblasts Possessing 
CAFs Characteristic
Gastric samples were harvested from 8-week-old Spraque-Dowley rats and extensively washed 
with sterile PBS to remove contaminating debris. Primary and secondary fibroblast culture was 
established as described previously [36]. The cells were cultured in DMEM containing 10% FBS and 
antibiotics (penicillin, streptomycin, and amphotericin B; Sigma A5955, Sigma-Aldrich, Saint Louis, 
MO, USA). The flasks were maintained in a humidified atmosphere of 5% CO2  at 37 °C, and the medium 
was changed every 2 days [36]. Before the co-incubation with fibroblasts, Hp strain was suspended 
in PBS, counted with Densimat Densitometer (bioMerieux, Marcy l'Etoile, France), and immediately 
transferred to the dishes containing fibroblasts. Then, 0.25 X 106 fibroblasts were infected with 1 X 109 
of live Hp and incubated in humidified atmosphere for 72 h (H p-AGFs). As for the control, gastric 
fibroblasts were cultured for 72 h in DMEM + 10% FBS (GF) [22,35- 37].
2.3. Isolation o f Hp-AGF and Normal Gastric Fibroblast (GF)-Conditioned Media
Gastric fibroblasts were co-cultured with Hp (cagA+vacA+) strain for 72 h [35]. Then, the Hp was 
washed out from fibroblasts and the medium was changed into DMEM + 10% FBS and antibiotics 
(penicillin, streptomycin, and amphotericin B; Sigma A5955, Marcy l'Etoile, France). The culture dishes 
were maintained in a humidified atmosphere of 5% CO2  at 37 °C for 4 h, and then the incubation fluid 
was again replaced with fresh portion of the medium. Fibroblasts were then left in fresh medium for 
96 h. After 96 h, the supernatant was collected (abbreviated in this paper as H p-AGF supernatant). 
The same procedure was applied to the control, normal gastric fibroblast culture (herein abbreviated as 
GF). To confirm the absence of viable bacteria, the Hp-AGF supernatants were applied on the plates 
with Columbia Agar with 5% fresh horse blood (BioMerieux, Marcy l'Etoile, France). The plates were 
incubated under microaerophilic conditions at 37 °C for up to 7 days. No visible signs of bacterial 
growth were detected. Additionally, the Hp-AGF secretome-target epithelial cells were checked for 
Hp 16S rRNA expression. All supernatants were stored in 4 °C up to two weeks.
2.4. Long-Term Influence o f Supernatants Collected from  Hp-AGFs and GFs on Epithelial RGM1 Cells
RGM1 rat gastric epithelial cells [38,39] were cultured in 5 mL of neat Hp-AGF supernatant for 
96 h on 6-well plates [22,37], then trypsinized (standard trypsinization technique) and resuspended 
in DM EM with antibiotics and without FBS (Sigma-Aldrich, Saint Louis, MO, USA). Then, the cells 
were seeded on the upper side of Transwell inserts containing native microporous membranes-pore 
diameter: 8 pm (Corning, Corning, NY, USA), at a density of 1 X 104 and allowed to transmigrate into 
the Hp-AGF supernatant during 24 h. The most activated post-EMT RGM1 cells which successfully 
transmigrated through the cell culture inserts were then checked for E- and N-cadherin expression,
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the indicators of the EMT. E-cadherin negative, N-cadherin positive post-EMT RGM1 cells (abbreviated 
in our present work as s.t.EMT+RGM1 cells) were then cultured in the supernatant from Hp-AGFs for 
at least 30 days (described in our present work as long-term RGM1 cells originating from EMT-positive 
short-term RGM1 cells l.t.EMT+RGM1 cells) in 25 cm2 flasks. The neat Hp-AGF supernatant was added 
in an amount of 4 mL and changed every 3 days. Simultaneously, RGM1 cells cultured for 96 h in GF 
supernatant (abbreviated as s.t.EM T- RGM1 cells) were then cultured in GF supernatant for at least 
30 days (described in our present study as long-term RGM1 cells originating from short-term EMT 
negative RGM1 cells (l.t.EMT- RGM1 cells). RGM1 cells were cultured in DMEM + 10% FBS (RGM1) 
for identical period of time (Scheme 1). During all experiments, the amounts of the media as well as 
the procedures applied to l.t.EMT+RGM1 cells, l.t.EMT- RGM1, and RGM1 cells were standardized.
Scheme 1. Flowchart of the experimental design.
The cells were then harvested and used for the mRNA expression analysis by RT-PCR and for 
protein expression (immunofluorescence and Western blot analysis).
2.5. RT-PCR Technique
Total cellular RNA was isolated according to the Chomczynski and Sacchi method [40] using Trizol 
Reagent (Invitrogen, Carlsbad, CA, USA). First strand cDNA was synthesized from total cellular RNA 
(2 pg) using Reverse Transcription System (Promega, Madison, WI, USA). Bacterial DNA was isolated 
from Hp strain 43504 using DNAzol Reagent (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer's protocol. The PCR was carried out from l.t.EMT+RGM1, l.t.EMT- RGM1, and RGM1 
cells, using 1 pg cDNA and Promega PCR reagent. Specific primers for Ki67, Cyclin D1, Bax, Bcl2, 
c-Myc, Oct4, Sox2, Klf4, p53, TGFfiR1, and TGFfiRl and 18S RNA (the verification of the RNA integrity) 
and 16S bacterial RNA were used (Sigma-Aldrich, Saint Louis, MO, USA). Sequences and annealing 
temperatures are listed in Table 1. PCR products were separated by electrophoresis in 2% agarose gel 
containing 0.5 pg/mL ethidium bromide and then visualized under UV light. Location of predicted 
PCR product was confirmed by using O'Gene Ruler 50 bp DNA ladder (ThermoFisher, Waltham, MA, 
USA) as standard marker.
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Table 1. Rat oligonucleotide primers for detection of mRNA and Hp oligonucleotide primer for 
detection of 16S rRNAby RT-PCR and PCR, annealing temperature and size of PCR products employed 
in the experimental protocol.
Gene Primer Sequence Size of PCR Product (bp)
Annealing 
Temp. (°Q
18S Forward 5' -GTTGGTTTTGATCTGATAAATGC-3' 143 60Reverse 5'-CATTAAATCAGTTATGGTTCCTTTG-3'
Bax Forward 5' -CTGCCAACCCACCCTGGTCT-3' 195 55Reverse 5'-TGGCAGCTGACATGTTTTCTG-3'
BCL2 Forward 5'-ACTGAGTACCTGAACCGGCATC-3' 108 60Reverse 5'-GGAGAAATCAAACAGAGGTCGC-3'
c-Myc Forward 5'-CCACACAGCCCACTGGTCCT-3' Reverse 5' -GGCTGGAGCATTTGCGGTTGTT-3' 163 60
Cyclin D1 Forward 5'-TGCTTGGGAAGTTGTGTTGG-3' 126 60Reverse 5' -AATGCCATCACGGTCCCTAC-3'
c-Myc Forward 5'-CCACACAGCCCACTGGTCCT-3' Reverse 5' -GGCTGGAGCATTTGCGGTTGTT-3' 163 60
Ki-67 Forward 5'-AACCAGGACTTTGTGCTCTGTAA-3' 209 60Reverse 5'-CTCTTTTGGCTTCCATTTCTTC-3'
Klf4 Forward 5' -TTCTCCACGTTCGCGTCCGG-3' 80 60Reverse 5' -TCTCGCCAACGGTTAGTCGGGG-3'
Oct4 Forward 5' -GGAGGGATGGCATACTGTGGACCT-3' 197 60Reverse 5'-TCCTGGGACTCCTCGGGACTAGG-3'
p53 Forward 5'-AGTGAAGGGACTAGCATTGTC-3' 243 60Reverse 5' -GGATGCCCGTGCTGCCGAGGAG-3'
Sox2 Forward 5'-AGAACCCCAAGATGCACAAC-3' 204 60Reverse 5' -CTCCGGGAAGCGTGTACTTA-3'
TGFp rec 2 Forward 5' -TGTGGCAGAGCGCTTCAGT-3' 95 60Reverse 5' -TGTTCAGGGAGCCGTCTTCT-3'
TGFp rec 1 Forward 5' -GCAGACTGGACCAGCAATGAC-3' 118 60Reverse 5'-CTGCAATCAGGATCACTGCAA-3'
Hp 16S Forward 5'-GTCAAGAGATCAGCCTATGTCC-3' 522 54Reverse 5' -TGGCAATCAGCGTCAGGTAATG-3'
2.6. Influence ofTGFpR1 Kinase Activity Receptor Inhibition on Phenotype o f Long-Term RGM1 Cells
Trypsinized l.t.EMT+RGM1, l.t.EMT- RGM1, and RGM1 cells were seeded at 8 X 106 cells per well 
and cultured for 96 h in Hp-AGF and GF supernatants enriched with TGFpR1 kinase activity inhibitor 
SB-431542 (10 pM/L) (Sigma-Aldrich, Saint Louis, MO, USA) and in DMEM + 10% FBS, respectively. 
After incubation period, total cellular RNA was isolated and RT-PCR was carried out (see above). 
Specific primers for Ki67, Cyclin D1, Bax, Bcl2, c-Myc, Oct4, Sox2, Klf4, and 18S RNA (the verification of 
the RNA integrity) were used (Sigma-Aldrich, Saint Louis, MO, USA) (Table 1).
2.7. Cell Proliferation
For proliferation assays, l.t.EMT+RGM1, l.t.EM T- RGM1, and RGM1 cells were seeded onto 
24-well plates at the density of 0.5 X 103 cells/cm2 and incubated in 2 mL of Hp-AGF supernatant, 
GF supernatant, and DMEM + 10% FBS, respectively, for 24, 48, 72, and 96 h. Cells were then 
harvested with trypsin and counted with Burker's hemocytometer. The same procedure was 
applied to l.t.EMT+RGM1, l.t.EMT- RGM1, and RGM1 cells with the addition of SB-431542 (10 pM/L) 
(Sigma-Aldrich, Saint Louis, MO, USA). Additionally, the l.t.EMT+RGM1 cells were placed in Hp-AGF 
supernatant and in DMEM + 10% FBS and recorded for 12 h using the Leica DM I6000B time-lapse 
system equipped with a temperature/CO2 chamber, the interference modulation contrast optics, and a 
cooled, digital DFC360FX CCD camera. Then, the number of cell divisions was referred to the total 
cell count.
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2.8. Western Blot
Cells were harvested with trypsin and proteins were extracted with the Subcellular Protein 
Fractionation Kit (Thermo scientific, Waltham, MA, USA). Total protein concentration was determined 
by nanodrop measurement. Proteins were separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) (NuPAGE, Invitrogen, Carlsbad, CA, USA) and transferred to 
nitrocellulose membranes (iBlot System Invitrogen, Carlsbad, CA, USA). Membranes were washed 
with Tris-buffered saline containing 0.05% Tween-20 (TBST) and blocked with 5% milk in TBST or 
3% BSA. Next, the membranes were incubated overnight with primary antibodies: anti-GAPDH, 
anti-E-cadherin, anti-N-cadherin, anti-LGR5, anti-TGFpR2, and anti-MEK1 at 4 °C and washed 
with TBST. Then, the membranes were incubated in the presence of HRP-conjugated secondary 
antibodies for 1 h at RT. The primary antibodies used were: anti-GAPDH (D16H11 Cell Signaling, 
Merck, Warsaw, Poland), anti-N-cadherin (GTX127345, Genetex, Irvine, CA, USA), anti-E-cadherin 
(ab212059, Abcam, Cambridge, UK), anti-LGR5 (ab76011, Abcam Cambridge, UK), anti-TGFpR2 
(GTX55814, Genetex, Irvine, CA, USA), and anti-MEK1 (GTX134234, Genetex, Irvine, CA, USA). 
The HRP-conjugated secondary antibodies used were: goat anti-rabbit IgG (ab6721, Abcam, Cambridge, 
UK) and goat anti-mouse (ab205719, Abcam, Cambridge, UK). Protein detection was carried out with 
chemiluminescence. Immunoreactive bands were visualized and quantified by imaging densitometry 
GelPro analyzer (Meyer Instruments, Huston, TX, USA).
2.9. Determination o f the Cells Ability to Release TGF§1
L.t.EMT+RGM1, l.t.EMT- RGM1, and RGM1 cells were placed on the 6 well plates in DMEM + 10% 
(0.3 X 106 cells per well) and allowed to release TGFp for 48 h. Then, the cells supernatants were 
collected and the concentration of TGFp1 was measured by ELISA kit no. orb50104 (Biorbyt, St. Louis, 
MO, USA) according to manufacturer protocol.
2.10. Image Acquisition and Immunofluorescence
Image acquisition was performed with a Leica DM I6000B microscope equipped with the total 
internal reflection fluorescence (TIRF), Nomarski interference contrast (DIC) modules. LAS-AF 
deconvolution software was used for image processing. For phenotype plasticity L.t.EM T+RGM1, 
l.t.EM T- RGM1 and RGM1 cells were trypsinized and seeded at 8 X 106 cells per well and each 
of them were cultured for 24 h in all 3 types of media: Hp-AGF supernatant, GF supernatant, 
and DMEM + 10% FBS. Then, the cells were photographed.
For the immunofluorescence, the a-SMA localization was analyzed in formaldehyde (3.7%)-fixed, 
Triton X-100 (0.1%) permeabilized cells. The mouse anti- a-SM A primary antibody (A2547, 
Sigma-Aldrich, Saint Louis, MO, USA) was used. Specimens were labeled with Alexa 
488-conjugatedgoat anti-mouse IgG (No. A11001, Invitrogen, Carlsbad, CA, USA) and counterstained 
with Hoechst 33258 (No. B2883, Sigma-Aldrich, St. Louis, MO, USA). For morphological and 
fluorescent staining evaluation, at least 20 microscopic fields of view were analyzed.
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2.11. Statistical Analyses
Statistical analysis of the data was performed with the use of Excel Software. Each variable was 
expressed as the mean (±S.E.M.). Statistical significance of difference was determined using analysis 
of variance (one-way ANOVA) test (Statistica Software). Further statistical analysis for post hoc 
comparisons was carried out with the Newman-Keuls test. Differences were considered statistically at 
p < 0.05.
3. Results
3.1. Long-Term Influence o f Hp-AGF Secretome Induces Phenotypical Changes in Pro-Invasive 
s.t.EMT+RGM1 Cells
We have previously shown that Hp activates paracrine loops between gastric fibroblasts and 
epithelial cells that result in the phenotypic shifts of RGM1 cells towards rear-front polarized, motile 
phenotype [14]. To estimate the long-term effects of these loops on the phenotype of RGM1 cells, 
we allowed these cells to transmigrate through microporous membranes [22]. The cells that most readily 
(24 h) penetrated the pores were characterized for E- and N-cadherin expression (s.t.EMT+RGM1; 
Figure 1A,B). These cells showed cadherin switch from E- to N-cadherin, which is characteristic for the 
EMT process. The progeny of these cells was then allowed to expand in the presence of the secretome 
from Hp-AGFs for 30 days (l.t.EMT+RGM1; Figure 1C). At the same time, the RGM1 cells were cultured 
for 96 h in normal gastric fibroblast (GF) supernatant (Figure 1D). In these cells, N-cadherin expression 
was almost absent, while E-cadherin was expressed (s.t.EMT- RGM1; Figure 1A ), which remains in 
agreement with our previous results [22]. Their progeny was allowed to expand in GF supernatant 
for 30 days. Such long-term incubation in the presence of GF secretome enabled us to establish a 
fibroblastoid RGM1 lineage (l.t.EMT- RGM1; Figure 1E). Western blot analysis revealed the induction 
of N-cadherin expression in these cells (Figure 1F). Analysis of a-SM A expression revealed that 
these cells incorporated a-SM A into stress fibers, indicating their myofibroblastic phenotype and GF 
secretome-induced epithelial-myofibroblast transition (EMyoT; Figure 1G). Concomitantly, an induction 
of N-cadherin observed after the short-term incubation (s.t.EMT+RGM1 cells) in Hp-AGF-conditioned 
medium (Figure 1A ) was followed by its down-regulation in the cells that underwent the long-term 
incubation (l.t.EMT+RGM1; Figure 1F). Moreover, a-SM A did not incorporate into stress fibers in 
l.t.EMT+RGM1 cells (Figure 1G ). These phenotypic shifts were accompanied by the increased TGFp1 
levels in Hp-AGF secretome [22]. Notably, l.t.EMT+RGM1 cells were able to release detectable amounts 
of TGFp1, as documented for cells allowed to secrete factors in DMEM + 10% FBS for 48 h by ELISA 
tests (Figure 1H ).
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Figure 1. Long-term influence of Hp-AGF secretome induces phenotypical changes in pro-invasive 
EMT+RGM1 cells. (A) Short-term cell Western blot analysis. Western blot analysis of the EMT process 
indicators: E- and N-cadherin in total cellular proteins isolated from short-term (96 h) RGM1 cells 
cultured in gastric fibroblast (GF) secretome (s.t.EMT- RGM1 cells) and from short-term (96 h) RGM1 cells 
cultured in Hp-AGF secretome which successfully transmigrated through the Transwell microporous 
membranes towards Hp-AGF secretome during 24 h (s.t.EMT+RGM1 cells). The 10 pg of total cellular 
proteins were loaded per each lane. (B) Nomarski contrast of s.t.EMT+ RGM1; (C) l.t.EMT+ RGM1; 
(D) s.t.EMT- RGM1; and (E) l.t.EMT- RGM1. (F) Long-term cell Western blot analysis. Western blot 
analysis of N-cadherin in total cellular proteins isolated from long-term (30 days) EMT-  RGM1 cells 
cultured in GF secretome (l.t.EMT- RGM1 cells) and from long-term (30 days) EMT+RGM1 cells cultured 
in the secretome from Hp-AGFs (l.t.EMT+RGM1), suggesting their reprogramming. The 10 pg of total 
cellular proteins were loaded per each lane. (G) Nomarski contrast and immunofluorescence of a-SMA
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distribution in original RGM1 cells, l.t.EMT- RGM1 and in l.t.EMT+RGM1 cells showing differentiation 
of l.t.EMT- RGM1 towards myofibroblasts. Green: a-SMA and blue: chromatin-Hoechst. (H)ForTGFß 
content in the secretome, cells were transferred to DMEM + 10% FBS and allowed for 48 h secretion.
The analysis showed that only l.t.EMT+RGM1 cells were able to secrete TGFß. Results are mean ± SEM 
of six independent experimental repeats. Asterisk indicates a significant change (p < 0.05) as compared 
to the control RGM1 value. (I) PCR analysis of the expression of 16S rRNA showing the absence of Hp 
contamination in l.t.EMT+RGM1 cells.
3.2. The Phenotypic Plasticity o f  l.t.EMT+RGMl Cells
L.t.EMT+RGM1 cells were characterized by plastic phenotype, which was modified by GF 
secretome. In the presence of Hp-AGF secretome, l.t.EMT+RGM1 acquired elongated mesenchymal-like 
shape with long, thin protrusions (Figure 2A). In the presence of GF secretome, l.t.EMT+ RGM1 cells 
retained the elongated, mesenchymal shape with long protrusions or acquired epithelial-like phenotype 
similar to that of untreated cells (Figure 2A,D). This effect was more pronounced in DMEM + 10% 
FBS (Figure 2A ,D). The cells presented high heterogenicity of morphology with the presence of 
epithelial-like cells and elongated mesenchymal phenotype with the characteristic polygonal shape, 
as shown in Figure 2A,D. In turn, l.t.EMT- RGM1 cells retained stable fibroblastoid-like morphology 
in all tested media (Figure 2B,E). Control RGM1 cells had elongated fibroblastoid morphology in the 
presence of Hp-AGF supernatant and epithelial in GF supernatant as well as in DMEM + 10% FBS 
(Figure 2C,F).
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Figure 2. The phenotypical plasticity of l.t.EMT+ RGM1 cells. Nomarski contrast of the 
stability of phenotype of (A) l.t.EMT+ RGM1 cells placed in Hp-AGF secretome, GF secretome, 
and DMEM + 10% FBS, respectively; (B) l.t.EMT- RGM1 cells placed for 24 h in Hp-AGF secretome, 
GF secretome, and DMEM + 10% FBS, respectively; (C) and of RGM1 cells placed for 24 h in Hp-AGF 
secretome, GF secretome, and DMEM + 10% FBS, respectively. L.t.EMT+ RGM1 cells were characterized 
by plastic phenotype which depended on the type of the medium suggesting EMT/MET switch 
ability. L.t.EMT-RGM1 cells cultured for 24 h in DMEM + 10% FBS possessed stable, fibroblastoid-like 
phenotype in all tested media. Histogram analysis of morphological cell diversity in (D) l.t.EMT+ RGM1 
cells placed in Hp-AGF secretome, GF secretome, and DMEM + 10% FBS, respectively; (E) l.t.EMT- RGM1 
cells placed for 24 h in Hp-AGF secretome, GF secretome, and DMEM + 10% FBS, respectively; (F) and 
of RGM1 cells placed for 24 h in Hp-AGF secretome, GF secretome, and DMEM + 10% FBS, respectively.
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The cells were counted according to cell morphology (non-polarized epithelioid cells vs rear-front 
polarized fibroblastoid cells). Blue arrows: sample fibroblastoid cells, red arrows: sample epithelioid 
cells. Results are mean ± SEM of three to six different independent experimental repeats. Asterisk 
indicates a significant difference between epithelial and fibroblastoid populations (p < 0.05).
3.3. TGFfiR1 Activation Participates in Both Pro-Pluripotent and Pro-Fibrotic RGM1 Reprogramming
The presence of TGFp1 in Hp-AGF-conditioned medium prompted us to identify the role of 
this cytokine in the regulation of Hp-AGF-reprogrammed cell plasticity. High levels of LGR5 were 
retained in l.t.EMT+RGM1 cell lineage (Figure 3A ). However, they were accompanied by the altered 
(in comparison to naive RGM1 cells) expression of Yamanaka factors at the mRNA level (Figure 3B). 
LGR5+l.t.EMT+RGM1 cells were characterized by the induction of Oct4 mRNA expression, while it 
was significantly lower in l.t.EMT- RGM1 cells and almost absent in RGM1 cells (Figure 3B) pointing to 
CSC-like phenotype of l.t.EMT+RGM1 cells. Concomitantly, l.t.EMT+RGM1 cells retained considerable 
Sox2 mRNA expression (the factor responsible for maintaining progenitor cell self-renewal) and slightly 
lowered, but still pronounced expression of c-Myc. Additionally, l.t.EMT+RGM1 cells displayed strongly 
down-regulated Klf4 encoding mRNA levels (Figure 3B). Thus, l.t.EMT+RGM1 cells were characterized 
by overall LGR5+/Oct4high/Sox2high/c-Mychigh/Klf4low pattern (Figure 3B). The involvement of TGFp 
and TGFpR1 activation in the stem-like commitment of l.t.EMT+RGM1 cells was further confirmed 
by the sensitivity of Oct4, Sox2, c-Myc, and Klf4 to the chemical inhibition of TGFpR1 signaling 
by SB431542. Consequently, the cells switched to overall Oct4low/Sox2low/c-Mychlgh/Kf4hlgh pattern 
(Figure 3C,D). On the other hand, LGR5- l.t.EMT- RGM1 displayed high Oct4 mRNA expression levels, 
accompanied by low Sox2 and c-Myc mRNA expression as well as Klf4 gene up-regulation (overall 
Oct4+/Sox2- /c-M yc- /Klf4+ phenotype; Figure 3B). Again, Oct4, Sox2, c-Myc, and Klf4 mRNA levels 
were sensitive to TGFpR1 inhibition by SB431542, which resulted in overall Oct4- /Sox2+ /c-Myc+/Klf4+ 
pattern (Figure 3C,D). Collectively, these data confirm that Hp-AGF and naive GF secretome induce 
alternative reprogramming scenarios, which at least partly depend on TGFpR1 signaling and result in 
differential LGR5/Oct4/Sox2/c-Myc/Klf4 expression pattern.
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Figure 3. TGFpR1 participates in both pro-pluripotent and pro-fibrotic RGM1 reprogramming.
(A) Western blot analysis of LGR5 in total cellular proteins isolated from l.t.EMT-  RGM1 cells, 
l.t.EMT+ RGM1 cells, and original RGM1 cells and semi-quantitative densitometry analysis of the 
ratio of selected proteins over GAPDH. The 10 pg of total cellular proteins were loaded per each lane.
(B) RT-PCR analysis of the expression of 18S mRNA and pluripotency indicators Yamanaka factors in 
l.t.EMT- RGM1 cells, l.t.EMT+RGM1 cells, and original RGM1 cells and the ratio of selected genes over 
18S mRNA. (C) RT-PCR analysis of expression of 18S mRNA and TGFpR1 signaling dependence of 
pluripotency indicators Yamanaka factors' mRNA expression in l.t.EMT- RGM1 cells, l.t.EMT+RGM1 
cells, and original RGM1 cells after addition of TGFpR1 kinase activity receptor inhibitor SB-431542 and 
the ratio of selected genes over 18S mRNA. (D) The overall analysis of Yamanaka factors' expression 
with and without SB-431542 in relation to control value which was taken as zero. The values lower than 
the controls are represented as negative bars; the values higher than control are represented as positive
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bars. Results are mean ± SEM of three to six independent experimental repeats. Asterisk indicates 
a significant change (p < 0.05) as compared to the control RGM1 value. Hash indicates a significant 
change (p < 0.05) as compared to the corresponding values without SB-431542.
3.4. Hp-AGF Secretome Induces Potentially Pro-Proliferative Phenotype ofl.t.EMT+ RGM1 Cells
We have checked the pro-proliferative potential of l.t.EMT+RGM1 cells cultured in Hp-AGF 
supernatant, l.t.EM T- RGM1 cells cultured in GF supernatant, and RGM1 cells cultured in 
DMEM + 10% FBS by evaluation of MEK1 protein expression. Western blot analysis showed 
highly accelerated MEK1 expression in l.t.EMT+RGM1 cells (Figure 4).
Figure 4. Hp-AGF secretome induces potentially pro-proliferative phenotype of l.t.EMT+RGM1 cells. 
Western blot analysis of MEK1 protein expression in total cellular proteins isolated from l.t.EMT- RGM1 
cells, l.t.EMT+RGM1 cells, and original RGM1 cells and semi-quantitative densitometry analysis of the 
ratio of selected proteins over GAPDH showing the increased expression of MEK1 protein. The 10 pg 
of total cellular proteins were loaded per each lane. Results are mean ± SEM of three independent 
experimental repeats. Asterisk indicates a significant change (p < 0.05) as compared to the control 
RGM1 value.
3.5. Hp-AGF Secretome Prompts TGFß-Dependent Proliferation ofl.t.EMT+ RGM1 Cells
To substantiate our hypothesis on the involvement of TGFßR1-dependent signaling in the 
regulation of RGM1 fate by fibroblast secretome, we focused on the proliferation of original 
l.t.EMT+RGM1 cells cultured in Hp-AGF supernatant, l.t.EMT- RGM1 cells cultured in GF supernatant, 
and RGM1 cells cultured in DMEM + 10% FBS (Figure 5A ). The number of l.t.EMT+RGM1 and 
RGM1 cells was comparable up to 96 h with statistically insignificant, however present increase for 
l.t.EMT+RGM1 at 96 h. In contrast, the number of l.t.EMT- RGM1 cells became significantly reduced at 
48 h and this inhibitory effect persisted up to 96 h (Figure 5A).
Differences between the proliferation rate of l.t.EMT+RGM1 and l.t.EM T- RGM1 populations 
(Figure 5A ) accompanied by their different patterns of pluripotency factors (Figure 3B) and their 
TGFßR1 dependence (Figure 3C,D) prompted us to estimate the involvement of TGFßR1 in RGM1 
growth control. Slight effect of Hp-AGF-conditioned medium on Ki67 and Cyclin D1 encoding mRNA 
levels in l.t.EMT+ RGM1 cells was accompanied by the slight down-regulation of Bax and pronounced 
up-regulation of Bcl2 in these cells (Figure 5B). Thus, anti-apoptotic effect of TGFßR1, which is 
present in Hp-AGF secretome, may account for the propagation of l.t.EMT+RGM1 cells under the 
selective pressure of Hp-AGF secretome. Furthermore, slight inhibition of l.t.EMT+RGM1 proliferation 
(Figure 5C) was accompanied by the up-regulation of Bax upon SB431542 administration (Figure 5D,E). 
Together with the effects on the expression of Ki67, Cyclin D1  mRNA, and less pronounced effect 
on Bcl2 mRNA (Figure 5D,E). These findings confirm the important role of TGFßR1 in this process. 
The percentage of dividing l.t.EMT+RGM1 cells allowed proliferating in TGFß1 rich Hp-AGF secretome 
and in DMEM + 10% FBS for 48 h was significantly higher in DMEM (Figure 5F).
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Figure 5. Hp-AGF secretome prompts TGFß-dependent proliferation of l.t.EMT+RGM1 cells. (A) For the 
proliferation assay, the l.t.EMT- RGM1 cells, l.t.EMT+ RGM1 cells, and original RGM1 cells were seeded 
onto 24-well plates (0.5 x 103 cells/cm2) in corresponding media. After 24,48,72, and 96 h, the cells were 
harvested, stained with trypan blue, and counted with Bürker's hemocytometer. (B) RT-PCR analysis of 
the expression of 18S mRNA and a panel of prosurvival and pro-proliferative factor mRNA expression 
in l.t.EMT- RGM1 cells, l.t.EMT+ RGM1 cells, and original RGM1 cells and the ratio of selected genes 
over 18S mRNA. (C) The influence of TGFßR1 signaling on cell proliferation was checked by the 
addition of 10 pM of TGFßR1 kinase activity receptor inhibitor SB-431542 to the l.t.EMT- RGM1 and 
l.t.EMT+RGM1 cells. As a reference, RGM1 cells cultured in DMEM + 10% FBS were used. (D) RT-PCR 
analysis of TGFßR1 signaling dependence of 18S mRNA and of prosurvival and pro-proliferative 
factors' mRNA expression in the presence of SB-431542. (E) The overall analysis of proliferative and 
prosurvival factor expression with and without SB-431542 in relation to the control value which was
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taken as zero. The values lower than the controls are represented as negative bars; the values higher 
than control are represented as positive bars (panel E). Percentage of dividing l.t.EMT+RGM1 cells 
in Hp-CAF secretome and in DMEM + 10% FBS (panel F). Results are mean ± SEM of four to six 
independent experimental repeats. Asterisk indicates a significant change (p < 0.05) as compared to the 
control RGM1 value. Hash indicates a significant change (p < 0.05) as compared to the corresponding 
values without SB-431542.
In GF-conditioned medium, l.t.EM T- RGM1 cells expressed considerably lower mRNA levels 
encoding Ki67 and Cyclin D1 than their l.t.EMT+RGM1 counterparts (Figure 5B), which correlated 
with their lower proliferation rate (Figure 5A ). In contrast to l.t.EMT+RGM1 cells, l.t.EM T- RGM1 
cells reacted to SB-431542 with the induction of proliferation (Figure 5C), correlated with the Ki67 
and Cyclin D1 gene up-regulation (Figure 5D,E). The expression of Bax  mRNA underwent slight 
increase, while the increase of Bcl2 mRNA was pronounced, which points to the inhibition of apoptosis 
(Figure 5D,E). Thus, TGFpR1 participates in the induction of anti-apoptotic effect in l.t.EMT+RGM1 
cells, while it inhibits proliferation and induces apoptosis of l.t.EMT- RGM1 cells. Collectively, our data 
confirm that Hp-AGF secretome prompts the enhanced proliferation of l.t.EMT+RGM1 under TGFp1 
stress, thus potentially facilitating Hp-induced gastric neoplasia.
3.6. Interrelations between TGFpR1 and TGFpR2 Activity Underlie Differential Microevolution Pattern o f 
l.t.EMT+RGM1 and l.t.EMT- RGM1 Cells
Apparently, secretome of gastric fibroblasts can switch between alternative developmental 
programs in RGM1 cells, depending on gastric fibroblast activation by Hp. Further experiments were 
performed to address the TGFp-related mechanisms underlying differential reactivity of l.t.EMT+RGM1 
and l.t.EM T- RGM1 cells to Hp-AGF and GF secretomes. Even though TGFpR1 mRNA levels were 
slightly down-regulated in l.t.EMT+RGM1 cells, TGFpR1 and TGFpR2 genes were activated in all 
tested cell types, both in the presence/absence of Hp-AGF secretome (Figure 6A). A more pronounced 
down-regulation of TGFpR2 mRNA expression in l.t.EMT+RGM1 cells (Figure 6A) was accompanied 
by the presence of two bands in Western blot analysis (Figure 6B). The lower band (ca. 65 kDa) had 
the molecular mass of unmodified TGFpR2 protein, whereas the second (75-80 kDa) corresponded 
to the glycosylated (active) TGFpR2 [41] (Figure 6B). These data point to partial inactivation of 
TGFpR2 in l.t.EMT+RGM1 cells as indicated by decreased levels of glycosylated TGFpR2 compared to 
l.t.EMT- RGM1 and RGM1 cells (Figure 6B). l.t.EMT+RGM1 cells were also characterized by decreased 
p53 mRNA level (Figure 6B).
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Figure 6. Differential microevolution pattern of RGM1 cells is associated with differently expressed 
TGFpRs. (A) RT-PCR analysis of the expression of 18S mRNA and of TGFfiRs and p53 mRNA in 
l.t.EMT- RGM1 cells, l.t.EMT+RGM1 cells, and original RGM1 cells and the ratio of selected genes over 
18S mRNA showing differentially expressed TGFfiRs mRNA and decreased mRNA expression of the 
tumor suppressor p53 in l.t.EMT+RGM1 cells. (B) Western blot analysis of TGFpR2 protein expression in 
total cellular proteins isolated from l.t.EMT- RGM1 cells, l.t.EMT+RGM1 cells, and original RGM1 cells 
and semi-quantitative densitometry analysis of the ratio of selected proteins over GAPDH, showing the 
presence of two forms of TGFpR2: naive and active, glycosylated form of TGFpR2 in l.t.EMT+RGM1 
cells. The 10 pg of total cellular proteins were loaded per each lane. Results are mean ± SEM of four to 
six independent experimental repeats. Asterisk indicates a significant change (p < 0.05) as compared to 
the control RGM1 value.
The data indicate that the collective TGFpR1/2 activation determines the expansion of pro-invasive 
RGM1 cells. Apparently, remaining TGFpRI activity along with TGFpR2 stimulation may negatively 
affect the proliferation of l.t.EM T- RGM1 cells in the presence of GFs secretome. This mechanism is 
potentially involved in the regulation of l.t.EMT- RGM1 cell stromal phenotype. In turn, TG Fpl can 
induce pro-neoplastic expansion of l.t.EMT+RGM1 cells under conditions of the reduced TGFpR2 
signaling. These findings underline the importance of TGFp signaling balance for the regulation of 
phenotypic fate of gastric epithelial cells.
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4. Discussion
Tumors comprise heterogeneous cell populations with distinct phenotypes, functions, and gene 
expression profiles [42]. Currently, a growing body of evidence supports the view that gastric 
cancer is initiated by single self-renewing CSC-like cells [30,43,44]. CSCs have the potential to 
self-renew and differentiate, thus initiating and sustaining the primary tumor growth and establishing 
metastases [33,45,46]. However, CSC origins still remain a matter of debate. During tumor development, 
CSCs cooperate with stromal fibroblasts that constitute the milieu for neoplastic loci and the barriers for 
immune system, concomitantly providing paracrine signals for tumor promotion [18,26- 29]. We have 
previously reported that normal gastric epithelial RGM1 cells undergo EMT-like phenotypic shifts, 
accompanied by inhibition of proliferation upon short-term (96 h) exposure to the secretome from 
Hp-infected gastric fibroblasts (Hp-AGFs) [22]. Here, we demonstrate that the prolonged cultivation of 
these post-EMT RGM1 cells in the presence of Hp-AGF secretome induces their reprogramming towards 
overall LGR5/Oct4 high phenotype, characteristic for phenotypically plastic stem-like neoplastic cells. 
In turn, the induction of RGM1 reprogramming towards the stromal a-SM A+ phenotype was seen in 
the presence of non-infected gastric fibroblast (GF) secretome, confirming the role of Hp in biasing the 
GF secretome towards pro-EMT activity. Apparently, TGFpR1/TGFpR2-dependent signaling switches 
participate in these alternative scenarios. Thus, paracrine loops within pre-cancerous loci govern the 
developmental fate of gastric epithelium via directing epithelial cells towards neoplastic or stromal 
differentiation program in aTGFpR1/R2-dependent/Hp regulated manner.
Apparently, "trans differentiation" processes and the induction of pluripotency factors promote the 
phenotypic plasticity of the cells within pre-neoplastic loci that facilitates the adaptation of alternative 
differentiation programs by gastric epithelial cells. We show that RGM1 cells can undergo alternative 
reprogramming events, depending on the Hp-modulated quality of humoral factors secreted by gastric 
fibroblasts. In the long-term presence of Hp-AGF secretome, RGM1 cells evolve towards the plastic 
Oct4+/LGR5+ phenotype (l.t.EMT+RGM1). Oct4 stands at the top of a hierarchy governing the regulation 
of both pluripotency and de-differentiation [30,47- 49]. In addition, LGR5+ GC cells have previously 
been shown to display stem cell-like features [50,51] and to regulate Oct4 levels. The overall LGR5/Oct4 
expression in phenotypically plastic l.t.EMT+RGM1 cells suggests their stem-cell like pluripotency 
commitment, which is potentially relevant for tumor development [30,52,53]. Thus, Hp induces 
fibroblast activation towards CAFs [35], which secrete factors increasing LGR5/Oct4-dependent stem 
cell-like potential of epithelial RGM1 cells, while non-infected fibroblasts are more predisposed to direct 
gastric epithelium towards the stromal (pro-fibrotic) phenotype. Such microevolution of fibroblastoid 
cells with overall Oct4+/LGR5-  phenotype was observed in RGM1 populations exposed for long 
periods to the GF secretome. l.t.EMT- RGM1 EMyoT-related phenotypic commitment is illustrated by 
a-SMA incorporation into stress fibers, l.t.EMT- RGM1 relative dormancy and stable (niche-secretome 
independent) myofibroblastoid phenotype.
Induction of complementary developmental scenarios in gastric epithelium may have a profound 
significance for Hp-induced initiation of gastric tumorogenesis. Nevertheless, further studies are 
necessary to address the multipotency and invasiveness of l.t.EMT+RGM1 cells, their Oct4+/LGR5+ 
expression accompanied by transient N-cadherin up-regulation, the post-EMT morphology/motility 
and apparent phenotypic plasticity suggest their CSC-like properties. Thus, we show the interrelations 
between mesenchymal phenotype and plasticity of cancer cells in the in situ GC model. Incomplete, 
partial EMT has previously been shown to account for the phenotypic plasticity (the ability to produce 
more than one phenotype) of cancer cells [24,30,33,54- 59]. These interrelations also participate in 
the EMT/MET-dependent GC progression, where epithelioid cancer cells undergo EMT to enter the 
metastatic cascade, whereas post-EMT CSCs undergo MET-directed differentiation after metastatic 
niche nesting [24,30,60,61]. Gastrointestinal CSCs were shown to have elevated expression levels 
of genes associated with stemness and pluripotency. Apart from Lgr5, Oct4, these include c-Myc, 
Sox2, and Klf4 [30,62- 66] discrete overall expression patterns of these factors in l.t.EMT+RGM1 and 
l.t.EMT- RGM1 cells confirm their involvement in the alternative EMT/EMyoT-related differentiation
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scenarios induced in gastric epithelial cells by their paracrine looping with Hp-AGFs/GFs, respectively. 
Apparently, prominent Klf4 and less pronounced c-Myc down-regulation facilitates pre-neoplastic 
phenotype of otherwise Oct4+/LGR5+ l.t.EMT+RGM1 cells, whereas LGR5/Sox2/c-M yc overall 
down-regulation is linked to pro-fibrotic/stromal phenotype of l.t.EM T- RGM1 cells. Consequently, 
these key modulators of pluripotency [33,67- 69] are closely linked not only to Hp-AGF-induced EMT 
of gastric epithelial cells but also participate in their non-infected fibroblast-induced EMyoT.
It has also been stated, that MEK1 and MEK2, which are related protein kinases involved in the 
Ras/Raf/MEK/ERK signal transduction cascade, participate in the regulation of cell cycle progression, 
cell differentiation, and proliferation [70], which suggests that the effect of the supernatant on 
proliferation rate could not account for the nutrient depletion by fibroblasts. The Ras-dependent 
ERK1/2 MAP kinase signaling pathway plays a central role in cell proliferation control and is frequently 
activated in different human cancers. Early studies have shown that expression of activated alleles of 
MEK1 is sufficient to deregulate the proliferation and trigger the morphological transformation of cell 
lines [70- 74]. Moreover, ERKs have been shown to be vital for CSC tumorogenicity [75].
Previously, short-time (96 h) incubation of RGM1 cells in the presence of Hp-AGF secretome 
has been shown to induce TGFfiR1/R2 mRNA up-regulation in these cells (especially TGFfiR2) [37]. 
It is well established that TGFp1 induces EMT during pathologic and physiologic fibrosis of normal 
tissues [22- 25,37,76- 82]. Pleiotropic effects of TGFp1 are also observed in cancer systems, where TGFp 
signaling can suppress or promote tumor initiation [80- 82] and progression [83- 85]. Relatively high 
Lgr5/Oct4/Sox2 mRNA levels, accompanied by p53 down-regulation [86,87], high proliferation rate, 
and TGFp1 secretion by l.t.EMT+RGM1 cells indicate that TGFp1 is involved in the induction of 
their CSC-like/proliferative state. The p53 down-regulation in l.t.EMT+RGM1 cells may sustain the 
activity of TGFp1 signaling in l.t.EMT+RGM1 cells at the levels promoting their viability. Furthermore, 
Klf4 down-regulation in l.t.EMT+RGM1 cells remains in concordance with this concept, as Klf4 promotes 
differentiation through TGFp1 target gene activation and myofibroblast formation [88]. In a parallel 
manner, Klf4 suppresses oncogenic TGFp1 signaling [89] via interactions with TGFp1 control elements 
(TCEs) [90]. TGFp1 is considered an immune biomarker which has also been linked to myocardial 
function and remodeling due to the regulation of valve fibrosis and calcification processes [91]. Notably, 
Klf4 has been shown to be down-regulated during tumor initiation and consecutively lost during 
GC progression [92- 94]. Furthermore, the involvement of TGFp1 in the regulation of pro-neoplastic
l.t.EMT+RGM1 phenotype is evidenced by the shifts in overall Oct4/c-Myc/Sox2/Klf4 mRNA levels 
following TGFpR1 inhibition. Additionally, anti-apoptotic activity of TGFpR1 is evidenced by some 
slight inhibition of l.t.EMT+RGM1 cell proliferation and Bax up-regulation induced by SB-431542. 
Thus, Hp-AGFs help to sustain the EMT-related CSC commitment of RGM1 cells and their viability 
in a TGFp1-mediated, TGFpR1-dependent, and Hp-modulated manner. This hypothesis was further 
confirmed by relatively strong impact of TGFpR1 inhibition on Oct4/c-Myc and Sox2 expression pattern 
in l.t.EM T- RGM1 cells. This finding indicates that TGFpR1 signaling remains active in these cells 
even in the environment characterized by lower level of TGFp1 [22] and is necessary to sustain their 
myofibroblastic phenotype. This observation was accompanied by SB431542-induced l.t.EMT- RGM1 
proliferation, which was correlated with Ki67, Cyclin D1, and Bax mRNA up-regulation back to the 
levels characteristic for naive RGM1 cells. The suppression of nuclear translocation of p-catenin 
into gastric cells along with the expression of the p-catenin target survival genes c-myc and cyclin 
D1 along with induction of apoptosis has recently been implicated as a potential mechanism of 
anti-cancer therapy [95]. Collectively, these observations confirm that non-infected GF secretome 
contains the range of TGFpR1 ligands that determine the array of developmental fates undertaken 
by RGM1 cells [96]. In conjunction with apparently opposite (inducing) effects of TGFp1/TGFpR1 on 
the phenotype/proliferation of l.t.EMT+RGM1 cells, this observation also indicates that these ligands 
cooperate with TGFp1 in biasing RGM reprogramming towards pro-neoplastic phenotype, while 
prompting EMyoT in the lower concentrations of TGFp1. Relatively low TGFpR2 expression/activity 
and p53 impairment [87,97,98] in l.t.EMT+RGM1 cells may suggest the role of TGFpR1/R2 interactions
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in the differential effects of Hp-AGF/GF secretome on RGM1 phenotype. Accordingly, the combination 
of TGFp1 with the other TGFpR influencing ligands impairs TGFpR2 activity, prompting the neoplastic 
program in RGM1 cells, whereas their myofibroblastic differentiation is induced in the low level of 
TGFp 1/presence of active TGFpR2. These findings need further research comprising direct and indirect 
influence of Hp on reciprocal interactions between different cellular components of gastric tissue taking 
place in vivo.
5. Conclusions
Collectively, our data confirm the primary role of the signals from Helicobacter pylori in the 
remodeling of gastric niche towards pro-neoplastic activity. In the absence of Hp, occasional lesions 
can temporarily help to establish potential paracrine loops between gastric stromal fibroblasts and 
epithelial cells, induce EMyoT in gastric epithelium, and prompt local tissue regeneration. On the 
perimeter of chronic Hp-induced lesions, where gastric fibroblasts are activated by local inflammation 
but not directly exposed to Hp signals, EMyoT of gastric epithelium can turn into the chronic state. 
On the other hand, direct Hp-generated stress results in further reprogramming of gastric fibroblasts 
and stabilization of paracrine loops between Hp-infected stromal fibroblasts possessing CAF-like 
characteristic [35] and gastric epithelium. Hp-infected stromal fibroblasts prompt reprogramming of 
normal gastric epithelial cells towards precancerous phenotype. These events are related to TGFp1 
release by Hp-AGF/epithelium, which modulates TGFpR1/R2-dependent signaling, induces EMT in 
non-cancerous epithelial cells, consequently prompting their pro-CSC-like phenotype. Consequently, 
the post-EMT cells are reprogrammed towards TGF p 1-dependent expansion and CSC-like commitment, 
providing the basis for their further EMT/MET plasticity. The Hp-activated fibroblast reprogramming of 
epithelial cells may thus potentiate the canonical pathway of Hp infection influence on epithelial cells.
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